Primary and secondary endpoints met in both TRuE-AD1 and TRuE-AD2 WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) today announced that the second randomized, vehicle-controlled, pivotal Phase 3 study from the TRuE-AD clinical trial program has met...
SAN DIEGO, Feb. 19, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has enrolled and...
Two additional published studies highlight WatchPAT’s accuracy and effectiveness in patients with Central Sleep Apnea (CSA) and Chronic Obstructive Pulmonary Disease (COPD) CAESAREA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR)...
CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) — Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today...
Positive Phase 2a stroke clinical data published ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a...
Email
Text